720 job cuts in the restructuring of GSK Belgium vaccine business

As of 24:00 on February 6, 31161 cases had been confirmed in China in total; leishenshan hospital began to transfer gradually; GSK Belgium vaccine business was reorganized and 720 people were laid off; Roche oral therapy reached the phase 3 clinical end point; Sanofi Btk inhibitor reached the phase 2 clinical end point As of 24:00 on February 6, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps have reported 31161 confirmed cases, 154 cured and discharged, 28985 confirmed cases (including 4821 severe cases), 636 dead cases and 26359 suspected cases 314028 close contacts and 186045 close contacts still under medical observation were found (official website of National Health Commission) After ten days and nights of struggle, on February 6, leishenshan hospital officially passed the acceptance of Wuhan urban construction and health department, and began to gradually transfer (Xinhua News Agency) GSK began a two-year restructuring of its Belgian vaccine business on Saturday, which will lay off 720 employees This staffing change will involve employees in R & D, manufacturing and global support functions In addition, GSK also decided to terminate the renewal of the temporary labor contract for 215 employees (Sina Medical News) On May 5, Sanofi announced its 2019 results with a net income of 36.126 billion euros In terms of products, drugs in the fields of tumor and immune inflammation contributed to the double-digit growth The most amazing one is dupilumab, which is used to treat atopic dermatitis It has exceeded 2 billion euros since it was listed in the market three years ago Sanofi is even more frank about its expectation that the peak sales of dupilumab will exceed 10 billion euros (medicine cube) Recently, Sonoma biotherapeutics, a company focusing on the development of autoimmune and degenerative disease regulatory T cell therapy, announced its establishment and completed a round of financing of 40 million US dollars Founded by four pioneers in Treg cell biology and cell therapy, the company is invested by arch venture partners, a well-known venture capital firm (chuangjianhui) Recently, Lumos diagnostics, a real-time diagnostic development company, announced the completion of a round of financing of US $15 million to support the development of its blood based real-time detection reagent, febridx Febridx was used to identify the clinical potential of febrile acute respiratory infection and to assist in the identification of viral and bacterial infections (chuangjianhui) Recently, Aberdeen announced the positive results of select PSA 1 clinical phase 3 trial Compared with placebo, rivoqtm (uPA acitinib, wupatinib) in two doses reached the main end point of ACR20 reaction in adult patients with active psoriasis arthritis who did not respond to one or more non biological remission drugs (DMARDs), and rivoq also showed significant improvement in disease signs and symptoms at various end points (Sina Medical News) Today, Roche's gene tag announced that its oral SMN2 gene splicing regulator risdiplam significantly improved the motor function of patients in the critical phase 3 trial of sunfish in the treatment of type 2 or type 3 spinal muscular atrophy (SMA) The trial is the first to show that risdiplam treatment improves motor function in adult SMA patients, the press release said (yaomingkant) Today, Sanofi announced that its oral Btk inhibitor sar442168 has reached the main end point in the phase 2B clinical trial for the treatment of patients with recurrent multiple sclerosis (MS), significantly reducing the occurrence of MS related disease activities (yaomingkant) The listing application of valsartan amlodipine tablets (I) (cyhs1800095) submitted by Beijing Baiao Pharmaceutical Co., Ltd according to the new 4 categories was approved by the State Drug Administration for listing, and the State Drug Administration has arranged to issue drug approval documents Baiao Pharmaceutical Co., Ltd has become the first manufacturer of this classic compound antihypertensive drug in China (medicine cube) Wanbond pharmaceutical, a wholly-owned subsidiary of wanbond new materials, recently received the approval document for supplementary application for clozapine tablets from the State Food and drug administration, which passed the consistency evaluation of quality and efficacy of generic drugs (Sina Medical News) On June 6, shisiyao group announced that the group has obtained the approval document of drug production registration of doxofylline injection (10ml: 0.1g) polypropylene ampoule packaging from the State Food and drug administration The product has passed the national review and approval consistent with the quality and efficacy of yuanyan research drug, and is the first one to obtain the production approval according to the new classification of four categories of chemicals (Sina Medical News) Zhejiang Pharmaceutical Co., Ltd recently received the approval document for drug supplement application of norfloxacin tablets (0.1g) approved and issued by the State Food and drug administration, which approved the drug to pass the quality and efficacy consistency evaluation of generic drugs (Sina Medical News)